Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating its lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The study, to be conducted at Rigshospitalet in Copenhagen, Denmark, will enroll up to 39 patients and prospectively select participants based on PTGR1 overexpression and DNA-damage-repair deficiency. This biomarker-guided approach is central to Lantern’s strategy of using its proprietary RADR platform to identify patients most likely to benefit from LP-184.
The trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies, addressing a significant unmet need in bladder cancer. According to the American Cancer Society, bladder cancer is the sixth most common cancer in the United States, with advanced stages having limited treatment options. The EMA clearance allows Lantern to expand its clinical development into Europe, leveraging the company’s AI-driven precision oncology strategy. The RADR platform, which uses artificial intelligence and machine learning to analyze genomic and clinical data, is instrumental in identifying biomarkers like PTGR1 that predict response to LP-184.
This development is important because it moves Lantern’s pipeline forward in a patient population with few therapeutic options. The Phase 1b/2 trial will provide initial efficacy and safety data, potentially supporting further registration studies. The company’s focus on biomarker-selected patients could improve trial success rates and accelerate the path to approval. Additionally, the study conducted at Rigshospitalet, a leading European cancer center, may enhance enrollment and data quality.
Lantern Pharma is also advancing other programs, including LP-284 for hematologic and solid tumors and LP-300 in the HARMONIC Phase 2 trial for never-smoker lung adenocarcinoma. The company’s wholly owned subsidiary, Starlight Therapeutics, is developing LP-184 for pediatric CNS cancers. Furthermore, Lantern’s withZeta.ai platform, a multi-agentic AI co-scientist, is now commercially available, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The news underscores the growing role of AI in oncology drug development. By using biomarkers to select patients, Lantern aims to improve outcomes and reduce trial costs. The EMA clearance is a regulatory milestone that validates the company’s approach and opens the door for broader European expansion. Investors and researchers will be watching the trial’s progress closely, as positive results could position LP-184 as a novel therapy for bladder cancer. More information can be found in the full press release at https://ibn.fm/6ku4F.
